Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Erlotinib in locally advanced head and neck cancer
NCT00392704Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Dec 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of bevacizumab and erlotinib in head and neck squamous cell carcinoma (HNSCC), sponsored by SCRI Development Innovations. Primary endpoint: Progression-Free Survival at 24 months. Started Dec 2006; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00392704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00392704.